Current Challenges and Emerging Approaches in IBD Management




This activity is provided by Integrity Continuing Education, Inc.


This activity is supported through an educational grant from Bristol Myers Squibb.


In recent years, advancements in the understanding of the immunopathology of ulcerative colitis (UC) have resulted in a significant expansion of therapeutic options targeting several different pathological mechanisms. Despite these improvements, many patients continue to experience suboptimal control of their condition, including frequent flares and steroid dependence. Delays in starting biologic therapy contribute to inadequate disease control, and insufficient knowledge among clinicians regarding the efficacy and safety of new and emerging agents continue to create management challenges in a subset of patients. This educational activity will increase clinician understanding of the importance of early biologic therapy by exploring new and emerging treatments in UC and providing tools to assist clinicians in engaging patients in their treatment and disease management to lead to better adherence and improved patient-centered outcomes.


Marla C. Dubinsky, MD
Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Center
Director, Marie and Barry Lipman IBD Preconception and Planning Clinic
Mount Sinai Kravis Children’s Hospital
Icahn School of Medicine at Mount Sinai
New York City, New York


Edward V. Loftus, Jr., MD
Professor of Medicine
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine
Rochester, Minnesota


Release date: August 26, 2022
Expiration date: August 26, 2023
Estimated time to complete activity: 60 minutes



This educational initiative has been designed for gastroenterologists, inflammatory bowel disease (IBD) specialists, fellows, advanced healthcare practitioners, and other healthcare team members involved in or interested in the care of patients with IBD.


Upon completion of this educational activity, participants should be able to:

  • Recognize the prevalence of suboptimal outcomes in IBD and understand the value of routine disease monitoring for successful management
  • Evaluate the benefits associated with the earlier introduction of new targeted therapies into the management of UC
  • Apply clinical data to clinical practice and incorporate new and emerging IBD therapies, once they become available, to improve patient outcomes
  • Develop an evidence-based treatment selection protocol and incorporate patient preferences into shared decision-making for the successful management of IBD

There are no fees for participating and receiving CME credit for this activity. During the period of August 26, 2022 through August 26, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 50%.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Marla C. Dubinsky, MD
Consultant: AbbVie, Inc., Arena Pharmaceuticals, Boehringer Ingelheim
Contracted Research: AbbVie Inc., Janssen Global Services, LLC
Stocks: Trellus Health, Inc.
Licensing Fee: Takeda Pharmaceuticals USA, Inc.

Edward V. Loftus, Jr., MD
Consultant: AbbVie, Inc., Arena, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, CALIBER, Celgene/Receptos, Eli Lilly, Interactive Scopes, Morphic Therapeutic, Ono Pharma, Protagonist, Scipher Medicine, Sun Pharma, Surrozen
Research Support: AbbVie, Inc., Bristol Myers Squibb, Celgene/Receptos, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Robarts Clinical Trials, Takeda, Theravance, Union Chimique Belge

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest